Studies have revealed that supplementing with IFN-γ by adoptive transfer of IFN-γ–producing lymphocytes or recombinant IFN-γ treatment inhibited bacteremia and pneumonia (50). The gene discussed is IFNG; the disease is susceptibility to pneumonia measurement.